Episode 11
On episode 11 we sit down with Paul Meister, Partner at Novalis LifeSciences, lead investor of our $100m Series B. Paul shares his perspectives on the potential for cell and gene therapies and the importance of data in driving the industry forward. Paul has extensive experience across pharmaceutical, biotech and life sciences, leading the merger of Thermo Electron and Fisher Scientific before becoming chair of Thermo Fisher Scientific and, later, chair and CEO of Syneos Health. When he caught up with Jason, he explained why he decided to join us on our mission to enable widespread patient access to cell and gene therapies and what he’s most excited about for the future of our partnership.
Further Information
- Learn more about Paul Meister